- Home
- RRR vs BEAM Comparison
RRR vs BEAM Comparison
Compare RRR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | BEAM |
|---|---|---|
| Founded | 1976 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RRR | BEAM |
|---|---|---|
| Price | $61.27 | $33.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $69.69 | $50.75 |
| AVG Volume (30 Days) | 776.8K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | 23.32 | ★ 82.31 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $2,011,483,000.00 | $24,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.62 | $33.77 |
| P/E Ratio | $81.01 | ★ N/A |
| Revenue Growth | 3.74 | ★ 33.33 |
| 52 Week Low | $50.03 | $15.60 |
| 52 Week High | $68.99 | $36.44 |
Technical Indicators
Market Signals| Indicator | RRR | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 60.55 |
| Support Level | $59.80 | $26.96 |
| Resistance Level | $63.34 | $36.44 |
| Average True Range (ATR) | 1.83 | 2.15 |
| MACD | 0.16 | 0.26 |
| Stochastic Oscillator | 67.76 | 88.60 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.